Remove Community Remove Complication Remove Information Remove Manufacturing
article thumbnail

The Most Engaging Decision You’ll Read All Year – Five Stars

FDA Law

FDA , Petitioners, a liquid nicotine manufacturer, sued FDA arguing that the Agency was arbitrary and capricious in rejecting the Petitioner’s Premarket Tobacco Application (“PMTA”) in violation of the Administrative Procedure Act (“APA”). Youth behavioral data was not specifically required but FDA encouraged such information.

article thumbnail

Urinary Incontinence Revisited: George Kuchel & Alison Huang

GeriPal

It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. That can be incredibly informative. We’re doing this also through the inpatient portal because we were trying to get as much information in there as possible.

IT 120
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Advance Care Planning Discussion: Susan Hickman, Sean Morrison, Rebecca Sudore, and Bob Arnold

GeriPal

Although, certainly when you start facing complications of serious illness, it is increasingly important to engage as individuals and conversations about goals, values, and preferences. Ideally, there’ll be a place in the chart that actually captures the name of that person and their contact information. Eric: Susan. Susan: Yeah.

Illness 72
article thumbnail

Buckle Up: DOJ Initiates Rulemaking to Reschedule Marijuana

FDA Law

For each factor, the NPRM noted that DEA’s position is that additional information during the rulemaking will further inform about the appropriate schedule for marijuana. The NPRM noted that DEA “has not yet made a determination as to its views of the appropriate schedule for marijuana.” NPRM at 44,607.

article thumbnail

Arsenicum album for Kerala school students: a bogus prophylaxis

Tiny Physician

However, there is no clinical trial on its effect on COVID 19 infection or its complications. Later, due to mass outrage from the scientific community, the label of ‘drug for treatment’ was changed to ‘immunity booster’ (5). Without well-designed clinical trials, how can we allow this drug to be given to our children?